CST, 12294S, CUEDC2 Antibody

Polyclonal Antibody for studying CUEDC2. Validated for Western Blotting,Immunoprecipitation. Highly specific and rigorously validated in-house, CUEDC2 Antibody (CST #12294) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:100 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity CUEDC2 Antibody recognizes endogenous levels of total CUEDC2 protein. Species Reactivity: Human, Monkey Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CUEDC2 protein. Antibodies are purified by protein A and peptide affinity chromatography. Background CUE domain-containing 2 (CUEDC2) protein is involved in regulating many cellular events including cell cycle regulation (1) and inflammation (2). Research studies have shown that CUEDC2 is highly expressed in many types of tumors, suggesting this protein may play a role in tumorigenesis (1,3). CUEDC2 is activated in early mitosis when it is phosphorylated by Cdk1 at Ser110. Phosphorylated CUEDC2 binds to Cdc20, which leads to the release of the anaphase-promoting complex/cyclosome (APC/C) from checkpoint inhibition, initiating anaphase. CUEDC2 is then dephosphorylated when cells exit mitosis (1). CUEDC2 is also an inhibitor of IKKα and IKKβ activation (2) as well as Jak1/Stat3 signaling (4). Research indicates that inappropriate regulation of CUEDC2 may contribute to tumor development by causing chromosome instability (1). Multiple studies have reported that CUEDC2 plays a role in the downregulation of progesterone receptor and estrogen receptor α, impairing the effects of progesterone on breast cancer cell growth. Conversely, research studies have shown that CUEDC2 and HER2 expression have a significant positive correlation in breast cancers, leading investigators to suggest that CUEDC2 could be an important target for breast cancer therapy (3,5). Alternate Names bA18I14.5; C10orf66; CUE domain containing 2; CUE domain-containing protein 2; CUED2; CUEDC2; MGC2491 Specification REACTIVITY: H Mk SENSITIVITY: Endogenous MW (kDa): 30-32 SOURCE: Rabbit